Catecholamines and their blockade in congestive heart failure

American Journal of Health-System Pharmacy

Volumn 55, Issue 7, 1998, Pages 676-682

  White, C Michael ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Cardiac drugs; Carvedilol; Catecholamines; Heart failure; Sympatholytic agents

Indexed keywords

ACEBUTOLOL; ADRENALIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPRENOLOL; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CARVEDILOL; CATECHOLAMINE; DOBUTAMINE; INOTROPIC AGENT; METOPROLOL; METOPROLOL TARTRATE; MILRINONE; NORADRENALIN; PLACEBO; PRACTOLOL; RENIN;

ADRENERGIC RECEPTOR BLOCKING; ADRENERGIC STIMULATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; EXERCISE TOLERANCE; HEART EJECTION FRACTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 0032055714     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/55.7.676     Document Type: Review

References (59)

1. Lily LS, ed. Pathophysiology of heart disease. Malvern, PA: Lea & Febiger; 1993:147-66.
2. Doval HC, Nul DR, Grancelli HO, for the Grupo de Estudia de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet. 1994; 344:493-8.
3. Arrigoni LW, Depew CC. Intensive care therapeutics. In: Koda-Kimble M, Young L, eds. Applied therapeutics. 5th ed. Vancouver, WA: Applied Therapeutics; 1992:12.1-12.29.
4. Cohn JN, Levine B, Olivari M et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984; 311:819-23.
5. Vagelos R, Nejedly M, Willson K et al. Comparison of low-dose versus high-dose enalapril therapy for patients with severe congestive heart failure. J Am Coll Cardiol. 1991; 17:275A. Abstract.
6. Levine TB, Francis GS, Goldsmith SR et al. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol. 1982; 49:1659-66.
7. Francis G, Benedict C, Johnstone D et al. Differences in neurohormonal activation in patients with left-ventricular dysfunction with and without heart failure. J Am Coll Cardiol. 1989; 13:246A. Abstract.
8. Bayless J, Norell M, Canepa-Anson R et al. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987; 57:17-22.
9. Swedburg K, Eneroth P, Kjekshus J. Cardiovascular hormones in relation to mortality in severe heart failure. J Am Coll Cardiol. 1989; 13:246A. Abstract.
10. Amercan College of Cardiology/American Heart Association Task Force on Practice Guidelines Committee on Evaluation and Management of Heart Failure. Guidelines for the evaluation and management of heart failure. Circulation. 1995; 92:2764-84.
11. Bristow MR, Ginsburg R, Umans V et al. Beta-1 and beta-2-adrenergic receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta-1 down regulation in heart failure. Circ Res. 1986; 59:297-309.
12. Fowler MB, Laser JA, Hopkins GL et al. Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation. 1986; 74:1290-302.
13. Bristow MR, Ginsburg R, Minobe W et al. Decreased catecholamine sensitivity and beta-adrenergic receptor density in failing human hearts. N Engl J Med. 1982; 307:205-11.
14. Brodde OE, Zerkowski HR, Maier W et al. Drug and disease induced changes of human cardiac beta-1 and beta-2 adrenoceptors. Eur Heart J. 1989; 10(suppl B):38-44.
15. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996:199-248.
16. Young RA, Ward A. Milrinone: a preliminary review of its pharmacological properties and therapeutic use. Drugs. 1988; 36:158-92.
17. Uretsky BF, Lawless CE, Verbalis JG et al. Combined therapy with dobutamine and amrinone in severe heart failure. Chest. 1987; 92:657-62.
18. Dies F, Krell MJ, Whitlow P et al. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure. Circulation. 1986; 74(suppl 2):11-38. Abstract.
19. German and Austrian Xamoterol Study Group. Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. Lancet. 1988; 1:489-93.
20. Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet. 1990; 336:1-6.
21. Katz AM. Cyclic adenosine monophosphate effects on the myocardium: a man who blows hot and cold with one breath. J Am Coll Cardiol. 1983; 2:143-9.
22. Plugfelder PW, O'Neill BJ, Ogilvie RI et al. A Canadian multicenter study of a 48h infusion of milrinone in patients with severe heart failure. Can J Cardiol. 1991; 7:5-10.
23. Packer M, Carver JR, Rodeheffer RJ et al., for the PROMISE Study Research Investigators. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991; 325:1468-75.
24. Dibianco R, Shabetai R, Koster W et al., for the Milrinone Multicenter Trial Group. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med. 1989; 320:677-83.
25. Eichorn EJ. The paradox of beta-adrenergic blockers for the management of congestive heart failure. In: Barnett DB, Pouleur H, Francis GS, eds. Congestive cardiac failure: pathophysiology and treatment. New York: Marcel Dekker; 1993: 213-50.
26. Ferguson DW, Abboud FM, Mark AL. Selective impairment of baroreflex-mediated vasoconstrictor responses in patients with ventricular dysfunction. Circulation. 1984; 69:451-60.
27. Levine TB, Francis GS, Goldsmith SR et al. The neurohormonal and hemodynamic response to orthostatic tilt in patients with congestive heart failure.
28. McLeod AA, Brown JE, Kuhn C et al. Differentiation of hemodynamic, humoral and metabolic responses to beta-1 and beta-2 adrenergic stimulation in man using atenolol and propranolol. Circulation. 1983; 67:1067-84.
29. Zimmerman BG, Gomes SK, Liano JC. Action of angiotensin on vascular nerve adrenergic endings. Facilitation of norepinephrine release. Fed Proc. 1972; 31:1344-50.
30. Roth RH. Action of angiotensin on adrenergic nerve endings: enhancement of norepinephrine biosynthesis. Fed Proc. 1972; 31:1358-64.
31. Threlkeld DS, Brantley A, Rudder LD et al., eds.. Drug facts and comparisons. St. Louis: Facts and Comparisons; 1996.
32. Waagstein F, Bristow MR, Swedberg K et al., for the Metoprolol in Dilated Cardiomyopathy Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993; 342:1441-6.
33. Swedberg K. Initial experience with beta-blockers in dilated cardiomyopathy. Am J Cardiol. 1993; 71(suppl c):30c-8c.
34. Pollock SG, Lystash J, Tedesco C et al. Usefulness of bucindolol in congestive heart failure. Am J Cardiol. 1990; 66:603-7.
35. Heesch CM, Marcoux L, Hatfield B et al. Hemodynamic and energetic comparison of bucindolol and metoprolol for the treatment of congestive heart failure. Am J Cardiol. 1995; 75:360-4.
36. Eichhorn EJ, Heesch CM, Barnett JH et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 1994; 24:1310-20.
37. Fischer ML, Gottlieb SS, Plotnick GD et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol. 1994; 23:943-50.
38. Ikram H, Fitzpatrick D, Crozier IG. Therapeutic controversies with use of beta-adrenoceptor blockade in heart failure. Am J Cardiol. 1993; 71(suppl c):54c-60c.
39. Currie PJ, Kelly MJ, McKenzie A et al. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. J Am Coll Cardiol. 1984; 3:203-9.
40. Heilbrunn SM, Shah P, Bristow MR et al. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 1989; 79:483-90.
41. Waagstein F, Caidahl K, Wallentin I et al. Long-term beta-blockade in dilated cardiomyopathy: effects of short and long term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation. 1989; 80:551-63.
42. Swedberg K, Hjalmarson A, Waagstein F et al. Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy. Br Heart J. 1980; 44:134-42.
43. Paolisso G, Gambardella A, Marrazzo G et al. Metabolic and cardiovascular benefits deriving from beta-adrenergic blockade in chronic congestive heart failure. Am Heart J. 1992; 123:103-9.
44. Waagstein F. The role of beta-blockers in dilated cardiomyopathy. Curr Opin Cardiol. 1995; 10:322-31.
45. Anderson B, Blomstrom-Lundqvist C, Hedner T et al. Exercise hemodynamics and myocardial metabolism during long-term beta-adrenergic blockade in severe heart failure. J Am Coll Cardiol. 1991; 18:1059-66.
46. McTavish D, Campoli-Rachards D, Sorkin EM. Carvedilol: a review of its pharmacologic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1993; 45:232-58.
47. Gilbert EM, Abraham WT, Olsen S et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996; 94:2817-25.
48. Gilbert EM, Olsen SI, Renund DG et al. Beta-adrenergic receptor regulation and left-ventricular function in idiopathic dilated cardiomyopathy. Am J Cardiol. 1993; 71(suppl c):23c-9c.
49. Yue TL Cheng HY, Lysko PG et al. Carvedilol, a new vasodilator and beta adrenergic antagonist, is an antioxidant and free radical scavenger. J Pharmacol Ther. 1992; 263:92-8.
50. Raftery EB. Vasodilating beta-blockers in heart failure. Eur Heart J. 1995; 16(suppl F):32-7.
51. Metra M, Nardi M, Giubbini R et al. Effects of short-term and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994; 24:1678-87.
52. Doughty RN, Whalley GA, Gamble G et al. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol. 1997; 29:1060-6.
53. Krum H, Sackner-Bernstein JD, Goldsmith RL et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 1995; 92:1499-506.
54. Packer M, Colucci WS, Sackner-Bernstein JD et al. Double-blind, placebo-controlled study of the effects of carvedilol on patients with moderate to severe heart failure: the PRECISE trial. Circulation. 1996; 94:2793-9.
55. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996; 334:1349-55.
56. Pfefer MA, Stevenson LW. Beta-adrenergic blockers and survival in heart failure. N Engl J Med. 1996; 334:1396-7. Editorial.
57. Bristow MR, Gilbert EM, Abraham WT et al., for the MOCHA Investigators. Carvedilol produces dose-related inprovements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996; 94:2807-16.
58. Colucci WS, Packer M, Bristow MR et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 1996; 94:2800-6.
59. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation. 1995; 92:212-8.